Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
  • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
  • C12N9/6478—Aspartic endopeptidases (3.4.23)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/23—Aspartic endopeptidases (3.4.23)
  • C12Y304/23045—Memapsin 1 (3.4.23.45), i.e. beta-secretase 2 or BACE2
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/23—Aspartic endopeptidases (3.4.23)
  • C12Y304/23046—Memapsin 2 (3.4.23.46), i.e. beta-secretase 1 or BACE
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0085—Brain, e.g. brain implants; Spinal cord
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
  • A61K9/5184—Virus capsids or envelopes enclosing drugs
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/16011—Herpesviridae
  • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
  • C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/16011—Herpesviridae
  • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
  • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
  • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

• compositions and methods for using presenilin genetic therapy constructs to treat Alzheimer's disease (AD) and other neurodegenerative diseases are, inter alia, compositions and methods for using presenilin genetic therapy constructs to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
• AD Alzheimer's disease
• Alzheimer's disease also known as Alzheimer disease, accounts for majority of neurodegenerative dementia and is the fourth leading cause of death in the United States after heart disease, cancer and stroke. It is characterized by a progressive loss of cognitive function, neurodegeneration, neurofibrillary tangles and amyloid plaques in the brains of patients. Although the progression speed varies in different patients, the average life expectancy following diagnosis is three to nine years. Currently, there is no treatment for Alzheimer's disease.
• Described herein is a novel approach that can be used to treat subjects with
• AD Alzheimer's disease
• PSEN1 and PSEN2 - are highly penetrant and account for ⁇ 90% of all mutations identified in familial AD (FAD), highlighting their importance in the pathogenesis of AD. More than 260 distinct mutations in PSEN1 have been reported, and they are dominantly inherited and mostly missense mutations.
• Pathogenic PSEN1 mutations act in cis to impair mutant PS1 function and act in trans to inhibit wild-type Presenilin-l (PS1) function (Hilor et al. J Neurosci 33: 11606-717 (2013); Zhou et al. Proc Natl Acad Sci USA 114: 12731-12736 (2017).
• the present disclosure is based, at least in part, on the unexpected discovery that providing a wild-type PSEN1 cDNA into immortalized MEFs carrying heterozygous or homozygous dominant negative Psenl mutations, a well-established familial Alzheimer’s disease model, rescued the impaired g-secretase activity in these cells. It is known that dominant negative mutations in the PSEN1 and PSEN2 genes are associated with early onset familial Alzheimer’s disease.
• PS2 presenilin-2
• PSEN1 and PSEN2 are part of g-secretase complex
• mutations in the PSEN1 and PSEN2 genes contribute to the accumulation of Amyloid beta (Ab) protein in Alzheimer’s disease patients.
• the present disclosure provides methods for effective gene therapy based on PSEN1 (to express PS1) and/or PSEN2 (to express PS2) for Alzheimer's disease and other
• neurodegenerative dementia representing a significant breakthrough in this disease area.
• a neurodegenerative disease, disorder or condition comprising administering to a subject in need of treatment a polynucleotide comprising a PSEN1 and/or PSEN2 gene or mRNA, e.g., encoding a PS1 or PS2 protein as described herein.
• the neurodegenerative disease, disorder or condition is Alzheimer’s disease, e.g., familial Alzheimer’s disease, e.g., characterized with one or more mutations in the PSEN1 and/or PSEN2 gene.
• the Alzheimer’s disease is sporadic Alzheimer’s disease.
• the Alzheimer’s disease is late-onset or early-onset Alzheimer’s disease.
• the neurodegenerative disease, disorder or condition is frontotemporal dementia, frontotemporal lobar degeneration, Pick’s disease, or Lewy body dementia.
• the neurodegenerative disease, disorder or condition is memory loss.
• the neurodegenerative disease, disorder or condition is cognitive decline or impairment.
• the cognitive impairment is mild cognitive impairment (MCI).
• the polynucleotide is a vector, e.g., a viral vector.
• polynucleotide sequence encoding a PS1 and/or PS2 protein or therapeutically active fragment thereof, optionally wherein the polynucleotides sequences are in vectors wherein the PS1 and/or PS2 encoding sequence is operably linked to a promotor that drives expression of the PS1 and/or PS2 in the brain. Also provided herein is the use of the polynucleotide sequences and vectors for use in treating a neurodegenerative disease, disorder or condition as described herein.
• the viral vector is an adeno-associated virus (AAV) vector.
• AAV vector is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, AAV11, AAV 12, AAV2/1, AAV2/2, AAV2/5, AAV2/6, AAV2/7, AAV2/8, AAV2/9, AAV2/rhlO, AAV2/AAV11, or AAV2/AAV12.
• the viral vector is a lentiviral vector or a retroviral vector.
• the polynucleotide encodes a presenilin 1 (PSEN1) gene or mRNA. In some embodiments, the polynucleotide encodes a presenilin 2 (PSEN2) gene or mRNA. In some embodiments, the polynucleotide encodes a presenilin 1 (PSEN1) and a presenilin 2 (PSEN2) gene or mRNA.
• the polynucleotide sequence encoding PS1 protein comprises a nucleotide sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of wild-type human presenilin-
• transcript variant 1 mRNA SEQ ID NO: l
• wild-type human presenilin-l transcript variant 2 mRNA SEQ ID NO: 2.
• the polynucleotide sequence encoding PS2 protein comprises a nucleotide sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of wild-type human presenilin-
• the polynucleotide sequence encoding a PS1 and/or PS2 protein e.g., presenilin 1 (PSEN1) and/or presenilin 2 (PSEN2) gene or mRNA, are operably linked to a promoter.
• PSEN1 presenilin 1
• PSEN2 presenilin 2
• the promoter is a pan neuronal promoter.
• the pan neuronal promoter is a synapsin I promoter.
• the pan neuronal promoter is a l.6-kb hybrid promoter composed of the CMV immediate- early enhancer, and CBA intron l/exon 1 (commonly called the“CAGGS promoter”).
• the promoter is a neuron subtype-specific promoter, e.g., an alpha-calcium/calmodulin kinase 2A promoter.
• the promoter is a cytomegalovirus (CMV) early
• CBA CMV enhance/chicken b-actin
• promoter comprising a CMV early enhancer element, the first exon and first intron of the chicken b- actin gene, and the splice acceptor of the rabbit b-globin gene (commonly call the“CAG promoter”).
• the polynucleotide sequence encoding a PS1 and/or PS2 protein is administered to the CNS of the subject in need of treatment.
• the polynucleotide encoding a PS1 and/or PS2 protein is administered to the CNS via intravenous delivery, intrathecal delivery, intracerebroventricular administration, stereotactic intraparenchymal administration, intracistemal administration, intracerebroventricular delivery, or stereotactic injection(s) into certain areas of brain, e.g., into the cistema magna, cerebral ventricles, lumbar intrathecal space, direct injection into the hippocampus and/or the neocortex.
• intravenous delivery intrathecal delivery
• intracerebroventricular administration stereotactic intraparenchymal administration
• intracistemal administration intracerebroventricular delivery
• stereotactic injection(s) into certain areas of brain, e.g., into the cistema magna, cerebral ventricles, lumbar intrathecal space, direct injection into the hippocampus and/or the neocortex.
• the polynucleotide is associated with (e.g., formulated for delivery using) an exosome or lipid-based nanoparticle (LNP).
• LNP lipid-based nanoparticle
• the neurodegenerative disease, disorder or condition is Alzheimer’s disease.
• the Alzheimer’s disease is familial Alzheimer’s disease.
• the Alzheimer’s disease is sporadic Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is sporadic Alzheimer’s disease.
• the Alzheimer’s disease is late-onset Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is late-onset Alzheimer’s disease.
• the neurodegenerative disease, disorder or condition is frontotemporal dementia, frontotemporal lobar degeneration, Pick’s disease, or Lewy body dementia.
• the neurodegenerative disease, disorder or condition is memory loss.
• the neurodegenerative disease, disorder or condition is cognitive decline or impairment.
• the cognitive impairment is mild cognitive impairment (MCI).
• FIGs 1A-B Decreased levels of PS1- and PSEN2-encoding mRNAs in hippocampal pyramidal neurons of sporadic AD brains.
• A Representative pictures of human hippocampal CA1 pyramidal neurons before (top) and after (bottom) laser capture microdissection (LCM).
• FIGs. 2A-B Decreased g-secretase activity in Psenl KI/+, KI/KI and Psenl-/- cells.
• A Western blotting using cell lysates from immortalized MEFs derived from embryos carrying various Psenl genotypes shows reduced g-secretase activity in PS1 L435F KI/+, KI/KI and PS 1 _/ cells, as indicated by decreased NICD production.
• MEFs were transfected with 1.25 pg Hesl-Luc and 5 ng Notch-DE. Antibodies specific for the N-terminus of PS1, NICD, and a-tubulin were used.
• FIGs. 3A-3B Introduction of WT hPSl rescues impaired g-secretase activity in mutant MEFs.
• A g-Secretase activity measured by NICD production is reduced in mutant MEF cells in a PS dosage dependent manner (WT > PS1 heterozygous KI or KO > homozygous PS1 KI or KO > DKO).
• B Restoring impaired g-secretase activity by WT hPSl.
• Increasing amounts of pCI-hPSl plasmid DNA, as indicated, are transfected into MEFs of varying genotypes. Western analysis showed that both PS1 NTF and NICD are restored in various PS mutant MEFs.
• Heterozygous L435F KI cells are labeled as KI/+ or PS1L435F/+.
• N 3 independent experiments. Data represent mean ⁇ SEM. *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001 (one-way ANOVA with Tukey’s post-hoc analysis).
• administration refers to the delivery or application of a composition to a subject or system.
• Administration to an animal subject may be by any appropriate route.
• administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal.
• biologically active refers to a characteristic of any substance that has activity in a biological system (e.g., cell culture, organism, etc.). For instance, a substance that, when administered to an organism, has a biological effect on that organism, is considered to be biologically active. Biological activity can also be determined by in vitro assays (for example, in vitro enzymatic assays). In particular embodiments, where a protein or polypeptide is biologically active, a portion of that protein or polypeptide that shares at least one biological activity of the protein or polypeptide is typically referred to as a “biologically active” portion. In some embodiments, a protein is produced and/or purified from a cell culture system, which displays biologically activity when administered to a subject.
• a control has its art-understood meaning of being a standard against which results are compared. Typically, controls are used to augment integrity in experiments by isolating variables in order to make a conclusion about such variables.
• a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparator. In one experiment, the“test” (i.e., the variable being tested) is applied. In the second experiment, the“control,” the variable being tested is not applied.
• a control is a historical control (i.e., of a test or assay performed previously, or an amount or result that is previously known).
• a control is or comprises a printed or otherwise saved record.
• a control may be a positive control or a negative control.
• the control may be a “reference control”, which is a sample used for comparison with a test sample, to look for differences or for the purposes of characterization.
• the term“gene therapy” refers to any treatment including the direct or indirect administration of a nucleic acid to a subject.
• a protein of therapeutic value is expressed from an administered nucleic acid.
• the term“identity” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes).
• the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence.
• the nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
• the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences.
• the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
• the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
• the percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an
• NWSgapdna.CMP matrix NWSgapdna.CMP matrix.
• sequence alignment programs are available and can be used to determine sequence identity such as, for example, Clustal. Improve, increase, or reduce:
• the terms“improve,”“increase” or“reduce,” or grammatical equivalents indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of the treatment described herein.
• A“control individual” is an individual afflicted with the same type and approximately the same severity of, e.g., Alzheimer’s disease, as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual(s) are comparable).
• Neurodegeneration is an individual afflicted with the same type and approximately the same severity of, e.g., Alzheimer’s disease, as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual(s) are comparable).
• neurodegeneration means a process in which one or more neurons are damaged, decrease in function, become dysfunctional, and/or are lost by death.
• Neurodegeneration encompasses both rapid, gradual, and intermediate forms. Accordingly, a neurodegenerative disease, condition, or symptom is one characterized in that the disease is typically associated with neuronal damage, and/or death.
• the term“subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate).
• a human includes pre- and post-natal forms.
• a subject is a human being.
• a subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease.
• the term“subject” is used herein interchangeably with“individual” or “patient.”
• a subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.
• An individual who is“suffering from” a disease, disorder, and/or condition has been diagnosed with or displays one or more symptoms of the disease, disorder, and/or condition.
• an individual who is“susceptible to” a disease, disorder, and/or condition has not been diagnosed with and/or may not exhibit symptoms of the disease, disorder, and/or condition.
• an individual who is susceptible to a disease, disorder, and/or condition may be characterized by one or more of the following: (1) a genetic mutation associated with development of the disease, disorder, and/or condition; (2) a genetic polymorphism associated with development of the disease, disorder, and/or condition; (3) increased and/or decreased expression and/or activity of a protein associated with the disease, disorder, and/or condition; (4) habits and/or lifestyles associated with development of the disease, disorder, and/or condition; (5) a family history of the disease, disorder, and/or condition; (6) reaction to certain bacteria or viruses; (7) exposure to certain chemicals.
• an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.
• the term“therapeutically effective amount” refers to an amount of a therapeutic protein which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment.
• the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
• the“therapeutically effective amount” refers to an amount of a therapeutic protein or composition effective to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and/or also lessening the severity or frequency of symptoms of the disease.
• a therapeutically effective amount is commonly administered in a dosing regimen that may comprise multiple unit doses.
• a therapeutically effective amount (and/or an appropriate unit dose within an effective dosing regimen) may vary, for example, depending on route of administration, on combination with other pharmaceutical agents.
• the specific therapeutically effective amount (and/or unit dose) for any particular patient may depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific pharmaceutical agent employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and/or rate of excretion or metabolism of the specific fusion protein employed; the duration of the treatment; and like factors as is well known in the medical arts.
• treatment refers to any administration of a substance (e.g., provided compositions) that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition.
• a substance e.g., provided compositions
• such treatment may be administered to a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
• treatment may be administered to a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
• treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition.
• treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
• PS1 refers to the presenilin-l protein
• PS2 refers to the presenilin-2 protein
• PS1 or PS2 is used to refer to mRNA or gene.
• the present disclosure provides, among other things, compositions and methods for treating subjects with Alzheimer's disease and other neurodegenerative diseases, disorders and conditions based on delivering functional presenilin-l (PS1) and/or presenilin-2 (PS2).
• PS1 functional presenilin-l
• PS2 presenilin-2
• the present disclosure contemplates gene therapy by providing a polynucleotide encoding a presenilin-l (PSEN1) and/or presenilin-2 (PSEN2) gene to a subject in need of treatment.
• PSEN1 presenilin-l
• PSEN2 presenilin-2
• PS1 and PS2 presenilin-2
• the present methods include gene therapy to express wild- type human Presenilin-l or Presenilin-2 in a subject suffering from or susceptible to a neurodegenerative disease, e.g., associated with a mutation (e.g., a dominant negative mutation) in PSEN1 or PSEN2, e.g., Alzheimer’s disease (e.g., familial AD patients carrying PSEN1 or PSEN2 mutations or sporadic AD patients).
• a gene therapy is, among other things, to enhance expression of PS1 or PS2 in the brains of familial or sporadic AD patients in order to correct or overcome a deficit in PS1 or PS2 expression and/or activity.
• a gene therapy method described herein result in increased expression of wild-type PS1 or PS2 in the brain, rescuing the impairment of g-secretase activity associated with PS1 or PS2 mutations.
• PSEN1 and PSEN2- are highly penetrant and account for ⁇ 90% of all mutations identified in familial AD (FAD), highlighting their importance in the pathogenesis of AD. More than 260 distinct mutations in PSEN1 have been reported, and they are dominantly inherited and mostly missense mutations.
• Pathogenic PSEN1 mutations act in cis to impair mutant PS1 function and act in trans to inhibit wild-type PS1 function (Hilor et al. J Neurosci 33: 11606-717 (2013); Zhou et al. Proc Natl Acad Sci USA 114: 12731-12736 (2017).
• dominant negative mutations cannot be rescued by expression of wild type protein (Herskowitz, I.
• Presenilin is the catalytic subunit of the g-secretase complex, which also includes Nicastrin, APH-l (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer 2), all of which are required for the assembly, stability and activity of the g-secretase complex.
• wild-type Presenilin protein may be able to replace the mutant Presenilin protein in the g-secretase complex.
• expression of wild type PS1 or PS2 proteins can be used to rescue the impairment of g-secretase expression and/or activity in AD patients.
• compositions described herein can equally be used to treat other neurodegenerative diseases, disorders or conditions.
• the methods described herein may be used to treat or reduce the risk of developing subjects with all types of Alzheimer’s disease including, but not limited to, familial and sporadic Alzheimer’s disease, early onset or late onset Alzheimer’s disease.
• the present methods may be used to treat or reduce the risk of development of early onset familial form of Alzheimer's disease (AD) that is associated with mutations in presenilin-l (PS1) and/or presenilin-2 (PS2) (Sherrington, et al, Nature 375:754-760 (1995); Rogaev, et al., Nature 376:775-778 (1995); Levy-Lahad, et al, Science 269:970-973 (1995); Hiltunen, et al, Eur.
• PS1 presenilin-l
• PS2 presenilin-2
• the present methods may be used to treat a subject that has a mutation in the PSEN1 or PSEN2 allele, e.g., a mutation that has a dominant negative effect on wild-type PS1/PS2 proteins.
• exemplary mutations include C410Y, Aex9, G548, D257A, L166P, R278I, L435F, G384A, Y115H, and L392V, as well as N141I, G206A, H163R, A79V, S290C, A260P, A426P, A431E, R269H, L271V, C1410Y, E280G, P264L, E185D, L235V, and M146V mutations (see, e.g., Heilig et al, J.
• Additional exemplary mutations that may have a dominant negative effect on wild-type PS proteins can include, but are not limited to, in PSEN-l: N32N; R35Q; D40del (delGAC); D40del (delACG); E69D; A79V; V82L; I83_M84del (DelIM, DI83/M84, AI83/AM84); I83T; M84V; L85P; P88L; V89L (G>T); V89L (G>C); C92S; V94M; V96F; V97L; T99A; F105C; F105I; F105L; F105V; R108Q; Lll3_Ill4insT (Intron4, InsTAC, p.
• TAT del Il67del
• I168T I168T
• Sl69del AS169, Serl69del, AS170
• S169L S169P
• S170F I168T
• Sl69del AS169, Serl69del, AS170
• S169L S169P
• S170F S170F
• the methods can include determining that a subject has such a mutation, e.g., using methods known in the art.
• Alzheimer's disease Gradually, cognitive impairment associated with Alzheimer's disease leads to memory loss, especially recent memories, disorientation and misinterpreting spatial relationships, difficulty in speaking, writing, thinking, reasoning, changes in personality and behavior resulting in depression, anxiety, social withdrawal, mood swings, distrust in others, irritability and aggressiveness, changes in sleeping habits, wandering, loss of inhibitions, delusions, and eventually death.
• the present methods may be used to treat other neurodegenerative diseases, disorders or conditions, including frontotemporal dementia, various types of memory loss, cognitive impairment including but not limited to mild cognitive impairment (MCI), or other conditions associated with loss of PS1, e.g., due to a mutation that creates a dominant negative isoform.
• MCI mild cognitive impairment
• Presenilin-1 PSEN1
• PSEN2 presenilin-2
• a presenilin-l (PS1) or presenilin-2 (PS2)-encoding polynucleotide suitable for use in the compositions and methods described herein can include a full length gene or a portion or fragment thereof that encodes a protein retaining substantial gamma secretase activity of the wild-type protein, e.g., at least 50% of the gamma secretase activity, or at least 60, 70, 80, 90, or 95% of the activity of the wild-type protein determined by (e.g., in in vitro g-secretase assays including those described in the Examples section, see also Watanabe et al., J.
• a suitable PS1- or PS2- enocoding polynucleotide has a sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the full length wild type genomic or cDNA PSEN1 or PSEN2 sequence, respectively.
• a suitable PSEN1 or PSEN2 gene encodes a protein sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the full-length wild type PS1 or PS2 protein sequence, respectively.
• PS1 and PS2 are normally cleaved into N- and C- terminal fragments that are the active form.
• PS-l is processed to give two fragments: an N- terminal 28 kDa fragment, and a C-terminal 18 kDa fragment; the principal endoproteolytic cleavage occurs at and near Met298 in the proximal portion of the large hydrophilic loop (Podlisny et al., Neurobiol Dis. l997;3(4):325-37; Marambaud et al, EMBO J.
• Sequences comprising or encoding these cleaved forms can also be used in the methods and compositions described herein, e.g., encoding amino acids 1-291, 1-292, 1-293, 1-294, 1-295, 1-296, 1-297, 1-298, or 1-299 of SEQ ID NO:5 or a corresponding fragment of SEQ ID NO:6-8.
• Table 1 GenBank Accession Nos.
• the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
• the length of a reference sequence aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%.
• the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
• the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
• the percent identity of two amino acid sequences can be assessed as a function of the conservation of amino acid residues within the same family of amino acids (e.g., positive charge, negative charge, polar and uncharged, hydrophobic) at corresponding positions in both amino acid sequences (e.g., the presence of an alanine residue in place of a valine residue at a specific position in both sequences shows a high level of conservation, but the presence of an arginine residue in place of an aspartate residue at a specific position in both sequences shows a low level of conservation).
• the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package, using a Blossum scoring matrix, e.g., with default values for gap penalty, gap extend penalty of 4, and frameshift gap penalty.
• a Blossum scoring matrix e.g., with default values for gap penalty, gap extend penalty of 4, and frameshift gap penalty.
• the PS1 protein contains a mutation.
• the mutation is a conservative substitution.
• Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa.
• Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein.
• glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V).
• Methionine (M) which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine.
• Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered“conservative” in particular environments (see, e.g. Table III of US20110201052; pages 13-15“Biochemistry” 2nd ED. Stryer ed (Stanford University); Henikoff et al, PNAS 1992 Vol 89 10915-10919; Lei et al, J Biol Chem 1995 May 19; 270(20): 11882-6).
• the methods include introducing one or more additional mutations into the human PS1 sequence (SEQ ID NOs:5 or 6).
• the sequence can be at least 80%, 85%, 90%, 95%, or 99% identical to at least 60%, 70%, 80%, 90%, or 100% of an human PS1.
• the methods include introducing one or more additional mutations into the human PS2 sequence (SEQ ID NOs:7 or 8).
• the sequence can be at least 80%, 85%, 90%, 95%, or 99% identical to at least 60%, 70%, 80%, 90%, or 100% of an human PS2.
• the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
• the length of a reference sequence aligned for comparison purposes is typically at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%.
• the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
• amino acid or nucleic acid“identity” is equivalent to amino acid or nucleic acid“homology”.
• the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
• the percent identity of two amino acid sequences can be assessed as a function of the conservation of amino acid residues within the same family of amino acids (e.g., positive charge, negative charge, polar and uncharged, hydrophobic) at corresponding positions in both amino acid sequences (e.g., the presence of an alanine residue in place of a valine residue at a specific position in both sequences shows a high level of conservation, but the presence of an arginine residue in place of an aspartate residue at a specific position in both sequences shows a low level of conservation).
• amino acids e.g., positive charge, negative charge, polar and uncharged, hydrophobic
• the comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
• Nucleic acids encoding a PS1 or PS2 polypeptide or therapeutically active fragment thereof can be incorporated into a gene construct to be used as a part of a gene therapy protocol.
• a gene construct for example, described herein are targeted expression vectors for in vivo delivery and expression of a polynucleotide that encodes a PS1 or PS2 polypeptide or active fragment thereof in particular cell types, especially cerebral cortical neuronal cells.
• Expression constructs of such components can be administered in any effective carrier, e.g., any formulation or composition capable of effectively delivering the component gene to cells in vivo.
• Approaches include insertion of the gene in viral vectors, preferably adeno-associated virus.
• Viral vectors typically transduce cells directly.
• Viral vectors capable of highly efficient transduction of CNS neurons may be employed, including any serotypes of rAAV (e.g., AAV 1 -AAV 12) vectors, recombinant or chimeric AAV vectors, as well as lentivirus or other suitable viral vectors.
• a polynucleotide encoding PS1 or PS2 is operably linked to promoter suitable for expression in the CNS.
• a neuron subtype-specific specific promoter such as the alpha-calcium/calmodulin kinase 2A promoter may be used to target excitatory neurons.
• a pan neuronal promoter such as the synapsin I promoter, may be used to drive PS1 or PS2 expression.
• Other exemplary promoters include, but are not limited to, a cytomegalovirus (CMV) early enhancer/promoter; a hybrid CMV enhance/chicken b-actin (CBA) promoter; a promoter comprising the CMV early enhancer element, the first exon and first intron of the chicken b-actin gene, and the splice acceptor of the rabbit b-globin gene (commonly call the“CAG promoter”); or a l.6-kb hybrid promoter composed of a CMV immediate-early enhancer and CBA intron l/exon 1 (commonly called the CAGGS promoter; Niwa et al.
• CMV cytomegalovirus
• CBA hybrid CMV enhance/chicken b-actin
• a typical approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g., a cDNA encoding a PS1 or PS2.
• a viral vector containing nucleic acid e.g., a cDNA encoding a PS1 or PS2.
• infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid.
• molecules encoded within the viral vector e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells that have taken up viral vector nucleic acid.
• a viral vector system particularly useful for delivery of nucleic acids is the adeno-associated virus (AAV).
• Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle.
• AAV vectors efficiently transduce various cell types and can produce long-term expression of transgenes in vivo.
• AAV vector genomes can persist within cells as episomes, vector integration has been observed (see for example Deyle and Russell, Curr Opin Mol Ther.
• AAV vectors such as AAV2 have been extensively used for gene augmentation or replacement and have shown therapeutic efficacy in a range of animal models as well as in the clinic; see, e.g., Mingozzi and High, Nature Reviews Genetics 12, 341-355 (2011); Deyle and Russell, Curr Opin Mol Ther. 2009 Aug; 11(4): 442-447; Asokan et al, Mol Ther. 2012 April; 20(4): 699-708.
• AAV vectors containing as little as 300 base pairs of AAV can be packaged and can produce recombinant protein expression.
• Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses are known in the art, e.g, can be found in Ausubel, et al., eds., Current Protocols in Molecular Biology, Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals.
• the use of AAV vectors to deliver constructs for expression in the brain has been described, e.g., in Iwata et al, Sci Rep. 20l3;3: l472; Hester et al, Curr Gene Ther. 2009 Oct;9(5):428-33; Doll et al., Gene Therapy 1996, 3(5):437-447; and Foley et al, J Control Release. 2014 Dec 28;l96:7l-8.
• the PS1 or PS2 encoding nucleic acid is present in a vector for gene therapy, such as an AAV vector.
• the AAV vector is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, AAV11, and AAV 12.
• a vector as described herein can be a pseudotyped vector.
• Pseudotyping provides a mechanism for modulating a vector’s target cell population.
• pseudotyped AAV vectors can be utilized in various methods described herein.
• Pseudotyped vectors are those that contain the genome of one vector, e.g., the genome of one AAV serotype, in the capsid of a second vector, e.g., a second AAV serotype. Methods of pseudotyping are well known in the art.
• a vector may be pseudotyped with envelope glycoproteins derived from Rhabdovirus vesicular stomatitis virus (VSV) serotypes (Indiana and Chandipura strains), rabies virus (e.g., various Evelyn-Rokitnicki-Abelseth ERA strains and challenge virus standard (CVS)), Lyssavirus Mokola virus, a rabies-related virus, vesicular stomatitis virus (VSV), Mokola virus (MV), lymphocytic choriomeningitis virus (LCMV), rabies virus glycoprotein (RV-G), glycoprotein B type (FuG-B), a variant of FuG-B (FuG-B2) or Moloney murine leukemia virus (MuLV).
• a virus may be pseudotyped for transduction of one or more neurons or groups of cells.
• pseudotyped vectors include recombinant AAV2/1, AAV2/2, AAV2/5, AAV2/6, AAV2/7, AAV2/8, AAV9, AAVrhlO, AAV11, and AAV 12 serotype vectors. It is known in the art that such vectors may be engineered to include a transgene encoding a human protein or other protein. In particular instances, the present disclosures can include a pseudotyped AAV9 or AAVrhlO viral vector including a nucleic acid as disclosed herein. See Viral Vectors for Gene Therapy: Methods and
• a particular AAV serotype vector may be selected based upon the intended use, e.g., based upon the intended route of administration.
• AAV vector constructs in gene therapy include methods of modification, purification, and preparation for administration to human subjects (see, e.g., Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003).
• AAV based gene therapy targeted to cells of the CNS has been described (see, e.g., U.S. patents 6,180,613 and 6,503,888).
• High titer AAV preparations can be produced using techniques known in the art, e.g., as described in U.S.
• a vector construct refers to a polynucleotide molecule including all or a portion of a viral genome and a transgene.
• gene transfer can be mediated by a DNA viral vector, such as an adenovirus (Ad) or adeno-associated virus (AAV).
• Ad adenovirus
• AAV adeno-associated virus
• Other vectors useful in methods of gene therapy are known in the art.
• a construct as disclosed herein can include an alphavirus, herpesvirus, retrovirus, lentivirus, or vaccinia virus.
• Adenoviruses are a relatively well characterized group of viruses, including over 50 serotypes (see, e.g., WO 95/27071, which is herein incorporated by reference). Adenoviruses are tractable through the application of techniques of molecular biology and may not require integration into the host cell genome.
• Recombinant Ad-derived vectors including vectors that reduce the potential for recombination and generation of wild-type virus, have been constructed (see, e.g., international patent publications WO 95/00655 and WO 95/11984, which are herein incorporated by reference). Wild-type AAV has high infectivity and is capable of integrating into a host genome with a high degree of specificity (see, e.g.
• Non-native regulatory sequences, gene control sequences, promoters, non-coding sequences, introns, or coding sequences can be included in a nucleic acid as disclosed herein.
• the inclusion of nucleic acid tags or signaling sequences, or nucleic acids encoding protein tags or protein signaling sequences, is further contemplated herein.
• the coding region is operably linked with one or more regulatory nucleic acid components.
• a promoter included in a nucleic acid as disclosed herein can be a tissue- or cell type- specific promoter, a promoter specific to multiple tissues or cell types, an organ-specific promoter, a promoter specific to multiple organs, a systemic or ubiquitous promoter, or a nearly systemic or ubiquitous promoter. Promoters having stochastic expression, inducible expression, conditional expression, or otherwise discontinuous, inconstant, or unpredictable expression are also included within the scope of the present disclosure.
• a promoter can include any of the above characteristics or other promoter characteristics known in the art.
• the gene delivery systems for the therapeutic gene can be introduced into a subject by any of a number of methods, each of which is familiar in the art.
• a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g., by intravenous injection, and specific transduction of the protein in the target cells will occur predominantly from specificity of transfection, provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof.
• initial delivery of the recombinant gene is more limited, with introduction into the subject being quite localized.
• the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection, e.g., optionally into the cistema magna, cerebral ventricles, lumbar intrathecal space, direct injection into
• delivery methods of Presenilin-expressing virus include intravenous, intrathecal,
• intracerebroventricular, intracistemal, and stereotactic intraparenchymal administration are intracerebroventricular, intracistemal, and stereotactic intraparenchymal administration.
• the methods can be further optimized via preclinical testing to achieve the best rescue of neurodegeneration, dementia, synaptic dysfunction and molecular alteration in presenilin conditional double knockout mice and presenilin- 1 knockin mice expressing FAD mutations.
• the pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is embedded.
• the pharmaceutical preparation can comprise one or more cells, which produce the gene delivery system.
• polynucleotides as disclosed herein for delivery to a target tissue in vivo are encapsulated or associated with in a nanoparticle.
• Methods for nanoparticle packaging are well known in the art, and are described, for example, in Bose S, et al (Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells. J. Virol. 78:8146. 2004); Dong Y et al. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:6068. 2005); Lobenberg R. et al (Improved body distribution of l4C-labelled AZT bound to nanoparticles in rats determined by radioluminography. J Drug Target 5: 171.1998); Sakuma S R et al
• one or more polynucleotides is delivered to a target tissue in vivo in a vesicle, e.g. a liposome (see Langer, Science 249: 1527-1533 (1990); Treat et al., in
• lipid-based nanoparticles are used; see, e.g., Robinson et al, Mol Ther. 2018 Aug l;26(8):2034-2046; US9956271B2.
• microvesicles can include microvesicles or a preparation thereof, that contains one or more therapeutic molecules - e.g., polynucleotides or RNA - described herein.
• the methods and compositions described herein can be applied to microvesicles of all sizes; in one embodiment, 30 to 200 nm, in one embodiment, 30 to 800 nm, in one embodiment, up to 2 um.
• a microvesicle preparation refers to a population of microvesicles obtained/prepared from the same cellular source. Such a preparation is generated, for example, in vitro, by culturing cells expressing the nucleic acid molecule of the instant invention and isolating microvesicles produced by the cells. Methods of isolating such microvesicles are known in the art (Thery et al., Isolation and
• exosomes from cell culture supernatants and biological fluids, in Current Protocols Cell Biology, Chapter 3, 322, (John Wiley, 2006); Palmisano et al., (Mol Cell Proteomics. 2012 August; 11(8):230-43) and Waldenstrom et al, ((2012) PLoS ONE 7(4): e34653.doi: l0. l37l/joumal.pone.0034653)), some examples of which are described herein.
• Such techniques for isolating microvesicles from cells in culture include, without limitation, sucrose gradient purification/separation and differential centrifugation, and can be adapted for use in a method or composition described herein. See, e.g., EP2010663B1.
• the microvesicles are isolated by gentle centrifugation (e.g., at about 300 g) of the culture medium of the donor cells for a period of time adequate to separate cells from the medium (e.g., about 15 minutes). This leaves the microvesicles in the supernatant, to thereby yield the microvesicle preparation.
• the culture medium or the supernatant from the gentle centrifugation is more strongly centrifuged (e.g., at about 16,000 g) for a period of time adequate to precipitate cellular debris (e.g., about 30 minutes). This leaves the microvesicles in the supernatant, to thereby yield the microvesicle preparation.
• the culture medium, the gentle centrifuged preparation, or the strongly centrifuged preparation is subjected to filtration (e.g., through a 0.22 um filter or a 0.8 um filter, whereby the microvesicles pass through the filter.
• the filtrate is subjected to a final ultracentrifugation (e.g. at about 110,000 g) for a period of time that will adequately precipitate the microvesicles (e.g. for about 80 minutes).
• the resulting pellet contains the microvesicles and can be resuspended in a volume of buffer that yields a useful concentration for further use, to thereby yield the microvesicle preparation.
• the microvesicle preparation is produced by sucrose density gradient purification.
• the microvesicles are further treated with DNAse (e.g., DNAse I) and/or RNAse and/or proteinase to eliminate any contaminating DNA, RNA, or protein, respectively, from the exterior.
• the microvesicle preparation contains one or more RNAse inhibitors.
• the molecules contained within the microvesicle preparation will comprise the therapeutic molecule.
• the microvesicles in a preparation will be a heterogeneous population, and each microvesicle will contain a complement of molecule that may or may not differ from that of other microvesicles in the preparation.
• the content of the therapeutic molecules in a microvesicle preparation can be expressed either quantitatively or qualitatively.
• One such method is to express the content as the percentage of total molecules within the microvesicle preparation.
• the therapeutic molecule is an mRNA
• the content can be expressed as the percentage of total RNA content, or alternatively as the percentage of total mRNA content, of the microvesicle preparation.
• the content can be expressed as the percentage of total protein within the microvesicles.
• therapeutic microvesicles, or a preparation thereof, produced by the method described herein contain a detectable, statistically significantly increased amount of the therapeutic molecule as compared to microvesicles obtained from control cells (cells obtained from the same source which have not undergone scientific manipulation to increase expression of the therapeutic molecule).
• the therapeutic molecule is present in an amount that is at least about 10%, 20%, 30% 40%, 50%, 60%, 70% 80% or 90%, more than in microvesicles obtained from control cells. Higher levels of enrichment may also be achieved.
• the therapeutic molecule is present in the microvesicle or preparation thereof, at least 2 fold more than control cell microvesicles. Higher fold enrichment may also be obtained (e.g., 3, 4, 5, 6, 7, 8, 9 or 10 fold).
• a relatively high percentage of the microvesicle content is the therapeutic molecule (e.g., achieved through overexpression or specific targeting of the molecule to microvesicles).
• the microvesicle content of the therapeutic molecule is at least about 10%, 20%, 30% 40%, 50%, 60%, 70% 80% or 90%, of the total (like) molecule content (e.g., the therapeutic molecule is an mRNA and is about 10% of the total mRNA content of the microvesicle). Higher levels of enrichment may also be achieved.
• the therapeutic molecule is present in the microvesicle or preparation thereof, at least 2 fold more than all other such (like) molecules. Higher fold enrichment may also be obtained (e.g., 3, 4, 5, 6, 7, 8, 9 or 10 fold).
• Example 1 Pyramidal neurons of sporadic Alzheimer disease (AD) patients exhibit reduced PSEN1 and PSEN2 mRNA levels
• Presenilin (PS) protein is the catalytic subunit of g-secretase, which is required for the production of Ab peptides. Mutations in the Presenilin-l (PSEN1) and Presenilin-2 (PSEN2) genes are associated with 90% of cases of familial Alzheimer’s disease (FAD). PSEN mutations associated with FAD and frontotemporal dementia cause loss of presenilin expression and presenilin function, leading to reduced g-secretase activity (Xia et al, Neuron. 2015 Mar 4;85(5):967-8l; Watanabe et al, J Neurosci. 2012 Apr l l;32(l5):5085-96;
• RNA preparation PicoPure RNA Isolation Kit, Life Technologies KIT0204
• qRT-PCR was performed using Superscript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Life Technologies). The sequence of the primers used are listed in Table 2.
• PSEN1 and PSEN2 mRNA levels were reduced in laser dissected pyramidal neurons from hippocampal CA1 pyramidal neurons of sporadic AD patients (FIGs. 1A-B).
• Example 2 Dose-dependent reduction of g-secretase activity in MEFs carrying heterozygous and homozygous PSEN1 mutations
• Mouse embryonic fibroblasts (MEFs) carrying various Psenl genotypes were maintained in media supplemented with 10% FBS and 1% penicillin and streptomycin.
• MEFs were immortalized by transfection with lpg CMV-SV40.
• MEFs transfected with CMV-SV40 were compared to MEFs transfected with CMV-GFP (lpg), which stopped dividing around passage 7.
• CMV-NotchAE (5ng) was transiently transfected into MEFs in 6-well plates using Lipofectamine LTX (ThermoFisher Scientific 15338030) per manufacturer’s instructions.
• Membranes were then incubated with dye-coupled secondary antibodies (goat anti-rabbit IRdye800, goat anti-mouse IRdye800, or goat anti-rabbit IRdye680 from Licor). Signals were quantified with the Odyssey Infrared Imaging System (LI-COR Bioscience) g-secretase activity measured by NICD production is reduced in L435F KI/+ MEFs and further reduced in KI/KI and PS1-/- MEFs (FIG. 3A).
• dye-coupled secondary antibodies goat anti-rabbit IRdye800, goat anti-mouse IRdye800, or goat anti-rabbit IRdye680 from Licor. Signals were quantified with the Odyssey Infrared Imaging System (LI-COR Bioscience) g-secretase activity measured by NICD production is reduced in L435F KI/+ MEFs and further reduced in KI/KI and PS1-/- MEFs (FIG
• Example 3 Dose-dependent rescue of g-secretase activity in MEFs with varying PS genotypes: RL7 +/+ , PS1 U35VI+ , PS1 +I , PS1 LU5FI L435F , PSP 1 and PS1 1 ; PS2 1
• NICD levels were reduced but detectable in p S1 L435F/ L435F ME Fs (“L435F KI/KI” MEFs) and PSP 1 MEFs (FIG. 3A), whereas t ie novo NICD production was undetectable by in vitro g-secretase assay using L435F KI/KI and PSP embryonic brains (Xia et al, Neuron. 2015 Mar 4;85(5):967-8l).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Medicinal Chemistry (AREA)
• Zoology (AREA)
• Neurology (AREA)
• Wood Science & Technology (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Neurosurgery (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Biophysics (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Virology (AREA)
• Hospice & Palliative Care (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Psychiatry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Psychology (AREA)
• Gastroenterology & Hepatology (AREA)
• Toxicology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Plant Pathology (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68617210

Family Applications (1)

Country Status (8)

Cited By (3)

Families Citing this family (4)

Citations (3)

Family Cites Families (41)

• 2019
  • 2019-05-22 EP EP19808081.4A patent/EP3796980A4/en active Pending
  • 2019-05-22 CN CN201980049127.3A patent/CN112739419A/zh active Pending
  • 2019-05-22 WO PCT/US2019/033616 patent/WO2019226832A1/en not_active Ceased
  • 2019-05-22 US US17/057,001 patent/US12497608B2/en active Active
  • 2019-05-22 AU AU2019272848A patent/AU2019272848A1/en not_active Abandoned
  • 2019-05-22 JP JP2020565341A patent/JP7587423B2/ja active Active
  • 2019-05-22 CA CA3100946A patent/CA3100946A1/en active Pending
• 2020
  • 2020-11-18 IL IL278813A patent/IL278813A/en unknown

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events